Event: The 4^th Annual Biopharma Innovation Conference 2019

Dates: September 10 – 11, 2019

Venue: Wyndham Bund East Shanghai, China

Weblink: www.bioinnovationforum.com

Contact: Marketing Department

Tel: +86 21 31602153

Email: Marketing@wbfgroup.com 

As the BioPharma industry grows in China & the Asian region. A part of our highly successful Biopharma series, the event, which attracts over 300 attendees, is the leading industry platform for Biopharma, biotech, Manufacturing Equipment, Bioscience and Analytical Equipment, Facility Design, Cold Chain, CMOs, CROs, Research institutes, investors, Technology and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China.

Covering topics ranging from latest regulations impacting to International partnering, from Biopharma R&D and Biotechnology to Biosimilar Development, from CMO and CRO, from Antibody development to Clinical Trials, from Biomanufacturing to Bioprocessing; from Upsteam: Cell Culture and Cell Line Development to Downstream: Production, Purification & Filtration, from Analytical and Protein engineering technology to Expression & Characterization, from AI and Smart to Automation and Digitalization, from Cutting edge technology & solutions to best Practice case studies, from business strategy, investment to innovation.

This is probably the most important event in the year on biopharma in terms of participants. It cannot be missed.

With over 40 speakers and estimation to bring over 300 Biopharma professionals, the key congress topics will cover:

·         New investment and outlook in china biopharma industry, Biotech Innovation and regulatory compliance

·         Round-table Discussions on Catering the Industry's Challenges and Opportunities to Asia's Landscape

·         Global Biopharma R&D Strategy Perspective, Antibody development, Clinical Design of Innovative Biopharma

·         Design and Engineering Improvement of Bispecific Antibodies and ADCs for drug ability

·         CFDAs priority review policy and impact on biosimilars, The current clinical trial landscape for new biosimilars, and expected pipelines

·         Innovation and technology breakthroughs for Biosimilar development, Discuss the advanced strategy and solutions to enhance biosimilars' bioprocessing stability and reliability

·         Market outlook for cell lines development across drug discovery, bioproduction, toxicity testing, and tissue engineering

·         The growing use of reagents and media, and technical best practice, Cell Culture and Purification Process Development Strategy from Analytical Approach

·         Clinical and commercial phase market outlook for CMOs in China, Antibody Continuous Process Scale-up

·         Analytical Characterization Strategies, Technology & Product Comparability, Leading Protein and Antibody Engineering Technology and Innovational Application

·         Advances in Upstream & Downstream Processing, Next Generation Bioprocessing, Global Updates on Manufacturing Technologies, Facility Design & Engineering Case Studies

·         Automation and Digitalisation Trends, AI in Biomanufacturing

On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests and the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and guided networking sessions for all professionals and management who are working for the Biopharma industry in Asia.